- Advanced search
- Guide to IMMUNOPHARMACOLOGY Portal
|Approved drug?||Yes (FDA (2014), EMA (2015))|
|International Nonproprietary Names|
|Blincyto® | bscCD19xCD3 | MEDI-538 | MT-103 | MT103 |
|Blinatumomab is a monoclonal antibody with anti-cancer effects. Its mechanism of action classifies this antibody as a member of the bi-specific T-cell engager (BiTE®) group of engineered antibodies. It was the first biologic of this class to gain clinical approval.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
|GtoPdb PubChem SID||178103956|
|Search PubMed clinical trials||blinatumomab|
|Search PubMed titles||blinatumomab|
|Search PubMed titles/abstracts||blinatumomab|